newsfilter
← Latest News
Business Wire·

KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update

KALV
  • KalVista Pharmaceuticals reported $49.1 million in global net product revenue for EKTERLY (sebetralstat) during the eight-month transition period ended December 31, 2025.
  • The company shifted its fiscal year-end from April 30 to December 31, covering a transition period from May 1, 2025, to December 31, 2025.
  • EKTERLY received 1,702 patient start forms in the US from its July 7, 2025, launch through February 2026, representing nearly 20% of the US patient population.
  • The US launch activated 724 unique prescribers, with the majority of Q4 2025 revenue driven by patient refills.
  • EKTERLY launched in Japan through partner Kaken Pharmaceutical Co., Ltd., becoming the first oral on-demand HAE therapy listed on the National Health Insurance reimbursement price list in that market.
  • Enrollment in the Phase 3 KONFIDENT-KID pediatric trial (ages 2–11) was completed one year ahead of schedule, with interim data to be presented at the 2026 Global Angioedema Leadership Conference in Madrid.
  • KalVista plans to file a US New Drug Application for pediatric use in Q3 2026, with a potential launch in 2027.
  • The International Pediatric HAE Guideline recommended EKTERLY as a first-line therapy for adolescents aged 12 and older.
  • Research and development expenses were $33.4 million for the eight months ended December 31, 2025, down from $52.2 million in the same period of 2024.
  • Selling, general, \& administrative expenses rose to $124.7 million for the period, primarily due to commercialization costs, compared to $64.9 million in 2024.
  • The company held approximately $300.2 million in cash, cash equivalents, \& marketable securities as of December 31, 2025.
  • EKTERLY is approved in the US, EU, UK, Switzerland, Australia, Singapore, \& Japan as the first oral on-demand treatment for HAE in patients aged 12 and older.
  • A conference call to discuss these results was scheduled for March 25, 2026, at 8:30 a.m. ET.